Top

Journal of Endocrinological Investigation

Open Access 16-05-2024 | Thyroid Cancer | Original Article

Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment

Authors: M. Borowczyk, M. Kaczmarek-Ryś, S. Hryhorowicz, M. Sypniewski, D. Filipowicz, P. Dobosz, M. Oszywa, M. Ruchała, K. Ziemnicka

Published in: Journal of Endocrinological Investigation

Abstract

Purpose

Differentiated thyroid cancer (DTC) presents a complex clinical challenge, especially in patients with distant metastases and resistance to standard treatments. This study aimed to investigate the influence of specific genes and their germline single nucleotide polymorphisms (SNPs) linked to both inflammatory processes and other neoplasms on the clinical and pathological characteristics of DTC, particularly their potential impact on radioiodine (RAI) treatment efficacy.

Methods

This retrospective analysis involved a cohort of 646 patients diagnosed with DTC after thyroidectomy. Study covering 1998–2014, updated in 2023, included 567 women and 79 men (median age: 49; range: 7–83). SNP selection targeted functional significance, while mutational status was assessed by pyrosequencing for comprehensive characterization. Patient genetic profiles were assessed for associations with disease characteristics, RAI response, and cancer pathology.

Results

Significant correlations emerged between certain SNPs and DTC features. Notably, the NOD2 c.802 T > C variant (rs2066842) was identified as a marker distinguishing between papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Moreover, the c.802 T allele was associated with an enhanced response to RAI treatment, indicating a more substantial decrease in posttreatment stimulated thyroglobulin (sTg) concentrations. The NFKB1A allele c.126A (rs696) exhibited connections with lower FTC stages and a reduced probability of multifocality.

Conclusion

This study explored the molecular mechanisms of particular SNPs, highlighting the role of NOD2 in innate immunity and the stress response, and its potential impact on RAI efficacy. This research underscores the clinical promise of SNP analysis and contributes to personalized treatment strategies for DTC, emphasizing the relevance of genetic factors in cancer progression and treatment outcomes.

van Houten P, Netea-Maier RT, Smit JW (2023) Differentiated thyroid carcinoma: an update. Best Pract Res Clin Endocrinol Metab 37:101687. https://doi.org/10.1016/j.beem.2022.101687CrossRefPubMed

Jarząb B, Dedecjus M, Lewiński A et al (2022) Diagnosis and treatment of thyroid cancer in adult patients—recommendations of polish scientific societies and the national oncological strategy. 2022 update [diagnostyka i leczenie raka tarczycy u chorych dorosłych - rekomendacje polskich towarzystw naukowych oraz narodowej strategii onkologicznej. aktualizacja na rok 2022]. Endokrynol Pol 73:173–300. https://doi.org/10.5603/EP.a2022.0028CrossRefPubMed

Yu L, Huang Z, Xiao Z et al (2024) Unveiling the best predictive models for early-onset metastatic cancer: insights and innovations (Review). Oncol Rep 51:60. https://doi.org/10.3892/or.2024.8719CrossRefPubMedPubMedCentral

Mo S, Zhou Z, Dai W et al (2020) Development and external validation of a predictive scoring system associated with metastasis of T1–2 colorectal tumors to lymph nodes. Clin Transl Med 10:275–287. https://doi.org/10.1002/ctm2.30CrossRefPubMedPubMedCentral

Vargas-Uricoechea H (2024) Autoimmune thyroid disease and differentiated thyroid carcinoma: a review of the mechanisms that explain an intriguing and exciting relationship. World J Oncol. https://doi.org/10.14740/wjon1728CrossRefPubMed

Heo DB, Won H-R, Tae K et al (2024) Clinical impact of coexistent chronic lymphocytic thyroiditis on central lymph node metastasis in low- to intermediate-risk papillary thyroid carcinoma: the MASTER study. Surgery 175:1049–1054. https://doi.org/10.1016/j.surg.2023.12.023CrossRefPubMed

Yang I, Yu JM, Chung HS et al (2024) Hashimoto thyroiditis and mortality in patients with differentiated thyroid cancer: the national epidemiologic survey of thyroid cancer in korea and meta-analysis. Endocrinol Metab (Seoul) 39:140–151. https://doi.org/10.3803/EnM.2023.1748CrossRefPubMed

Park SK, Ryoo J-H, Kim M-H et al (2024) Association between eight autoimmune diseases and thyroid cancer: a nationwide cohort study. Thyroid 34:206–214. https://doi.org/10.1089/thy.2023.0353CrossRefPubMed

Borowczyk M, Janicki A, Dworacki G et al (2019) Decreased staging of differentiated thyroid cancer in patients with chronic lymphocytic thyroiditis. J Endocrinol Invest 42:45–52. https://doi.org/10.1007/s40618-018-0882-4CrossRefPubMed

10.

Santana VB, Krüger VM, Abrahão MCY et al (2024) Chronic lymphocytic thyroiditis with oncocytic metaplasia influences pd-l1 expression in papillary thyroid carcinoma. Head Neck Pathol 18:14. https://doi.org/10.1007/s12105-024-01618-5CrossRefPubMed

11.

Pan J, Ye F, Yu C et al (2021) Papillary thyroid carcinoma landscape and its immunological link with hashimoto thyroiditis at single-cell resolution. Front Cell Dev Biol 9:758339. https://doi.org/10.3389/fcell.2021.758339CrossRefPubMedPubMedCentral

12.

Dos Santos Valsecchi VA, Betoni FR, Ward LS, Cunha LL (2024) Clinical and molecular impact of concurrent thyroid autoimmune disease and thyroid cancer: from the bench to bedside. Rev Endocr Metab Disord 25:5–17. https://doi.org/10.1007/s11154-023-09846-wCrossRefPubMed

13.

Pani F, Caria P, Yasuda Y et al (2022) The immune landscape of papillary thyroid cancer in the context of autoimmune thyroiditis. Cancers (Basel) 14:4287. https://doi.org/10.3390/cancers14174287CrossRefPubMed

14.

Liu T-T, Yin D-T, Wang N et al (2023) Identifying and analyzing the key genes shared by papillary thyroid carcinoma and Hashimoto’s thyroiditis using bioinformatics methods. Front Endocrinol (Lausanne) 14:1140094. https://doi.org/10.3389/fendo.2023.1140094CrossRefPubMed

15.

Ma B, Chen X, Zhao Z et al (2022) Coexisting CLT in PTC is an independent predictor of tumor aggressiveness for patients aged under 55: a retrospective analysis of 635 patients. BMC Endocr Disord 22:55. https://doi.org/10.1186/s12902-022-00945-4CrossRefPubMedPubMedCentral

16.

Sakiz D, Sencar ME, Calapkulu M et al (2021) The effects of chronic lymphocytic thyroiditis on clinicopathologic factors in papillary thyroid cancer. Endocr Pract 27:1199–1204. https://doi.org/10.1016/j.eprac.2021.07.011CrossRefPubMed

17.

Cho YY, Chung YJ, Kim HS (2021) Malignancy rate of bethesda class iii thyroid nodules based on the presence of chronic lymphocytic thyroiditis in surgical patients. Front Endocrinol (Lausanne) 12:745395. https://doi.org/10.3389/fendo.2021.745395CrossRefPubMed

18.

Aydoğan Bİ, Mutlu ABB, Yüksel S et al (2021) The association of histologically proven chronic lymphocytic thyroiditis with clinicopathological features, lymph node metastasis, and recurrence rates of differentiated thyroid cancer. Endocr Pathol 32:280–287. https://doi.org/10.1007/s12022-020-09653-yCrossRefPubMed

19.

Ryu YJ, Yoon JH (2020) Chronic lymphocytic thyroiditis protects against recurrence in patients with cN0 papillary thyroid cancer. Surg Oncol 34:67–73. https://doi.org/10.1016/j.suronc.2020.03.008CrossRefPubMed

20.

Lee I, Kim HK, Soh EY, Lee J (2020) The association between chronic lymphocytic thyroiditis and the progress of papillary thyroid cancer. World J Surg 44:1506–1513. https://doi.org/10.1007/s00268-019-05337-9CrossRefPubMed

21.

Osorio C, Ibarra S, Arrieta J et al (2020) Association between chronic lymphocytic thyroiditis and papillary thyroid carcinoma: a retrospective study in surgical specimens. Rev Esp Patol 53:149–157. https://doi.org/10.1016/j.patol.2019.07.004CrossRefPubMed

22.

Borowczyk M, Szczepanek-Parulska E, Dębicki S et al (2019) Differences in mutational profile between follicular thyroid carcinoma and follicular thyroid adenoma identified using next generation sequencing. Int J Mol Sci 20:E3126. https://doi.org/10.3390/ijms20133126CrossRef

23.

Borowczyk M, Szczepanek-Parulska E, Dębicki S et al (2020) High incidence of FLT3 mutations in follicular thyroid cancer: potential therapeutic target in patients with advanced disease stage. Ther Adv Med Oncol 12:1758835920907534. https://doi.org/10.1177/1758835920907534CrossRefPubMedPubMedCentral

24.

Agrawal N, Akbani R, Aksoy BA et al (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676–690. https://doi.org/10.1016/j.cell.2014.09.050CrossRefPubMedCentral

25.

Fagin JA, Nikiforov YE (2023) Progress in thyroid cancer genomics: a 40-year journey. Thyroid 33:1271–1286. https://doi.org/10.1089/thy.2023.0045CrossRefPubMed

26.

Liu JB, Ramonell KM, Carty SE et al (2023) Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes. Surgery 173:252–259. https://doi.org/10.1016/j.surg.2022.05.048CrossRefPubMed

27.

Borowczyk M, Szczepanek-Parulska E, Olejarz M et al (2019) Evaluation of 167 gene expression classifier (gec) and thyroseq v2 diagnostic accuracy in the preoperative assessment of indeterminate thyroid nodules: bivariate/hroc meta-analysis. Endocr Pathol 30:8–15. https://doi.org/10.1007/s12022-018-9560-5CrossRefPubMed

28.

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020CrossRefPubMedPubMedCentral

29.

Romei C, Elisei R (2021) A narrative review of genetic alterations in primary thyroid epithelial cancer. Int J Mol Sci 22:1726. https://doi.org/10.3390/ijms22041726CrossRefPubMedPubMedCentral

30.

Kalarani IB, Sivamani G, Veerabathiran R (2023) Identification of crucial genes involved in thyroid cancer development. J Egypt Natl Canc Inst 35:15. https://doi.org/10.1186/s43046-023-00177-0CrossRefPubMed

31.

Gejoe G, Yadev IP, Kumaran A et al (2022) Coexistence of histologically proven chronic lymphocytic thyroiditis with other thyroid disorders: a retrospective study. Surg J (N Y) 08:e131–e135. https://doi.org/10.1055/s-0041-1740626CrossRef

32.

Mincer DL, Jialal I (2024) Hashimoto Thyroiditis. In: StatPearls. StatPearls Publishing, Treasure Island (FL)

33.

Ralli M, Angeletti D, Fiore M et al (2020) Hashimoto’s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev 19:102649. https://doi.org/10.1016/j.autrev.2020.102649CrossRefPubMed

34.

Liao X, Zhang D (2021) The 8th edition american joint committee on cancer staging for hepato-pancreato-biliary cancer: a review and update. Arch Pathol Lab Med 145:543–553. https://doi.org/10.5858/arpa.2020-0032-RACrossRefPubMed

35.

Giovanella L, D’Aurizio F, Algeciras-Schimnich A et al (2023) Thyroglobulin and thyroglobulin antibody: an updated clinical and laboratory expert consensus. Eur J Endocrinol 189:R11–R27. https://doi.org/10.1093/ejendo/lvad109CrossRefPubMed

36.

Raney BJ, Barber GP, Benet-Pagès A et al (2024) The UCSC genome browser database: 2024 update. Nucleic Acids Res 52:D1082–D1088. https://doi.org/10.1093/nar/gkad987CrossRefPubMed

37.

Martin FJ, Amode MR, Aneja A et al (2023) Ensembl 2023. Nucleic Acids Res 51:D933–D941. https://doi.org/10.1093/nar/gkac958CrossRefPubMed

38.

Liu G, Loraine AE, Shigeta R et al (2003) NetAffx: affymetrix probesets and annotations. Nucleic Acids Res 31:82–86CrossRefPubMedPubMedCentral

39.

Sondka Z, Dhir NB, Carvalho-Silva D et al (2024) COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res 52:D1210–D1217. https://doi.org/10.1093/nar/gkad986CrossRefPubMed

40.

Wickham H, Averick M, Bryan J et al (2019) Welcome to the tidyverse. J Open Source Softw. https://doi.org/10.21105/joss.01686CrossRef

41.

Dessau RB, Pipper CB (2008) ’’R"–project for statistical computing. Ugeskr Laeger 170:328–330PubMed

42.

Lüdecke D (2018) ggeffects: tidy data frames of marginal effects from regression models. J Open Source Softw. https://doi.org/10.21105/joss.00772CrossRef

43.

Guzik P, Więckowska B (2023) Data distribution analysis – a preliminary approach to quantitative data in biomedical research. J Med Sci 92:e869–e869. https://doi.org/10.20883/medical.e869CrossRef

44.

Almeida-da-Silva CLC, Savio LEB, Coutinho-Silva R, Ojcius DM (2023) The role of NOD-like receptors in innate immunity. Front Immunol. https://doi.org/10.3389/fimmu.2023.1122586CrossRefPubMedPubMedCentral

45.

Babamale AO, Chen S-T (2021) Nod-like receptors: critical intracellular sensors for host protection and cell death in microbial and parasitic infections. Int J Mol Sci 22:11398. https://doi.org/10.3390/ijms222111398CrossRefPubMedPubMedCentral

46.

Mukherjee T, Hovingh ES, Foerster EG et al (2019) NOD1 and NOD2 in inflammation, immunity and disease. Arch Biochem Biophys 670:69–81. https://doi.org/10.1016/j.abb.2018.12.022CrossRefPubMed

47.

Safran M, Rosen N, Twik M et al (2021) The GeneCards Suite. In: Abugessaisa I, Kasukawa T (eds) Practical Guide to Life Science Databases. Springer Nature, Singapore

48.

Gabanyi I, Lepousez G, Wheeler R et al (2022) Bacterial sensing via neuronal Nod2 regulates appetite and body temperature. Science. https://doi.org/10.1126/science.abj3986CrossRefPubMed

49.

Homer CR, Richmond AL, Rebert NA et al (2010) ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in crohn’s disease pathogenesis. Gastroenterology 139(1630–1641):1641.e1–2. https://doi.org/10.1053/j.gastro.2010.07.006CrossRef

50.

Keestra-Gounder AM, Byndloss MX, Seyffert N et al (2016) NOD1 and NOD2 signalling links ER stress with inflammation. Nature 532:394–397. https://doi.org/10.1038/nature17631CrossRefPubMedPubMedCentral

51.

Pei G, Zyla J, He L et al (2021) Cellular stress promotes NOD1/2-dependent inflammation via the endogenous metabolite sphingosine-1-phosphate. EMBO J. https://doi.org/10.15252/embj.2020106272CrossRefPubMedPubMedCentral

52.

Kaczmarek-Ryś M, Hryhorowicz ST, Lis E et al (2021) Crohn’s disease susceptibility and onset are strongly related to three nod2 gene haplotypes. J Clin Med 10:3777. https://doi.org/10.3390/jcm10173777CrossRefPubMedPubMedCentral

53.

Tian Y, Li Y, Hu Z et al (2010) Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis. Int J Colorectal Dis 25:161–168. https://doi.org/10.1007/s00384-009-0809-9CrossRefPubMed

54.

Liu J, He C, Xu Q et al (2014) NOD2 polymorphisms associated with cancer risk: a meta-analysis. PLoS ONE 9:e89340. https://doi.org/10.1371/journal.pone.0089340CrossRefPubMedPubMedCentral

55.

Kaczmarek-Ryś M, Ziemnicka K, Hryhorowicz ST et al (2015) The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hered Cancer Clin Pract. https://doi.org/10.1186/s13053-015-0030-5CrossRefPubMedPubMedCentral

56.

Mu Z, Zhang X, Sun D et al (2024) Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer. J Clin Endocrinol Metab 109:1231–1240. https://doi.org/10.1210/clinem/dgad697CrossRefPubMed

57.

Zangara MT, Johnston I, Johnson EE, McDonald C (2021) Mediators of metabolism: an unconventional role for NOD1 and NOD2. Int J Mol Sci 22:1156. https://doi.org/10.3390/ijms22031156CrossRefPubMedPubMedCentral

58.

Stanciu AE, Hurduc A, Stanciu MM et al (2023) Portrait of the inflammatory response to radioiodine therapy in female patients with differentiated thyroid cancer with/without type 2 diabetes mellitus. Cancers (Basel) 15:3793. https://doi.org/10.3390/cancers15153793CrossRefPubMed

59.

De la Vieja A, Riesco-Eizaguirre G (2021) Radio-iodide treatment: from molecular aspects to the clinical view. Cancers (Basel) 13:995. https://doi.org/10.3390/cancers13050995CrossRefPubMed

60.

Cunha LL, Morari EC, Guihen ACT et al (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 77:918–925. https://doi.org/10.1111/j.1365-2265.2012.04482.xCrossRef

61.

Shin E, Koo JS (2022) Cell component and function of tumor microenvironment in thyroid cancer. Int J Mol Sci 23:12578. https://doi.org/10.3390/ijms232012578CrossRefPubMedPubMedCentral

62.

Xi C, Zhang G-Q, Sun Z-K et al (2020) Interleukins in thyroid cancer: from basic researches to applications in clinical practice. Front Immunol 11:1124. https://doi.org/10.3389/fimmu.2020.01124CrossRefPubMedPubMedCentral

63.

Zečkanović A, Maver A, Ristić S et al (2021) Potential protective role of a NOD2 polymorphism in the susceptibility to multiple sclerosis is not associated with interferon therapy. Biomed Rep 15:100. https://doi.org/10.3892/br.2021.1476CrossRefPubMedPubMedCentral

64.

Zhang T, Ma C, Zhang Z et al (2020) (2021) NF-κB signaling in inflammation and cancer. MedComm 2:618–653. https://doi.org/10.1002/mco2.104CrossRef

65.

Zhang M, Huang J, Tan X et al (2015) Common polymorphisms in the nfkbia gene and cancer susceptibility: a meta-analysis. Med Sci Monit 21:3186–3196. https://doi.org/10.12659/msm.895257CrossRefPubMedPubMedCentral

66.

Li L, Zhang Z-T (2019) Genetic association between nfkbia and nfkb1 gene polymorphisms and the susceptibility to head and neck cancer: a meta-analysis. Dis Markers 2019:6523837. https://doi.org/10.1155/2019/6523837CrossRefPubMedPubMedCentral

67.

Barnabei L, Laplantine E, Mbongo W et al (2021) NF-κB: At the borders of autoimmunity and inflammation. Front Immunol. https://doi.org/10.3389/fimmu.2021.716469CrossRefPubMedPubMedCentral

68.

Kilfoy BA, Zheng T, Holford TR et al (2009) International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 20:525–531. https://doi.org/10.1007/s10552-008-9260-4CrossRefPubMed

69.

Hryhorowicz S, Ziemnicka K, Kaczmarek-Rys M et al (2015) Cyclin D1 and CHEK2 polymorphic variants as low risk susceptibility alleles in DTC patients. Hered Cancer in Clin Pract 13:A15. https://doi.org/10.1186/1897-4287-13-S1-A15CrossRef

70.

Hryhorowicz S, Ziemnicka K, Kaczmarek-Ryś M et al (2015) CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma. Oncol Lett 9:442–448. https://doi.org/10.3892/ol.2014.2617CrossRefPubMed

Title: Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment
Authors: M. Borowczyk
M. Kaczmarek-Ryś
S. Hryhorowicz
M. Sypniewski
D. Filipowicz
P. Dobosz
M. Oszywa
M. Ruchała
K. Ziemnicka
Publication date: 16-05-2024
Publisher: Springer International Publishing
Keywords: Thyroid Cancer
Thyroid Cancer
Thyroid Cancer
Thyroiditis
Published in: Journal of Endocrinological Investigation
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-024-02389-0

2024 ESC Congress

Noise pollution dangerous for heart health

02-09-2024
Myocardial Infarction
News

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Antihypertensives: more effective at morning or night?

02-09-2024
Hypertension
News

Low Lp(a) levels unlikely to increase the risk of diabetes

02-09-2024
Type 2 Diabetes
News

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

ERS Congress 2024

Springer Medicine

Germline polymorphisms of the NOD2 pathway may predict the effectiveness of radioiodine in differentiated thyroid cancer treatment

Abstract

Purpose

Methods

Results

Conclusion

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials

ERS Congress 2024

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

2024 ESC Congress

Noise pollution dangerous for heart health

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

At a glance: The STEP trials